SC
GILD icon

Scotia Capital’s Gilead Sciences GILD Stock Holding History

Scotia Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-30,000
Closed -$2.5M – 800
2016
Q2 		$2.5M Buy
+30,000
New +$2.66M 0.05% 233

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Scotia Capital's GILD Position: Q2 2026 in Review

Scotia Capital reduced its Gilead Sciences (GILD) stake by 11% in Q2 2026, selling an estimated $2.03M and leaving 127,501 shares worth $16.1M. The position accounts for 0.06% of the portfolio, ranked #174.

Scotia Capital first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $23.2M in Q2 2015. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Scotia Capital held 127,501 shares of Gilead Sciences worth $16.1M as of Q2 2026.
  • Scotia Capital sold 15,431 Gilead Sciences shares in Q2 2026, an estimated $2.03M.
  • Gilead Sciences made up 0.06% of Scotia Capital's portfolio in Q2 2026, its #174 holding.
  • Scotia Capital first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Scotia Capital's Gilead Sciences position peaked at $23.2M in Q2 2015.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.